Metabolic enzyme polymorphisms and susceptibility to acute leukemia in adults

American Journal of PharmacoGenomics

Volumn 2, Issue 2, 2002, Pages 79-92

  Morgan, G J ^a   Smith, M T ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACYLTRANSFERASE; ALKYLATING AGENT; BENZENE; CARMUSTINE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOTOXIC AGENT; DACARBAZINE; DNA; DNA TOPOISOMERASE INHIBITOR; EPIPODOPHYLLOTOXIN; GLUTATHIONE TRANSFERASE; LOMUSTINE; MYELOPEROXIDASE; NUCLEOTIDE; PROCARBAZINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TEMOZOLOMIDE; URACIL;

ACUTE LEUKEMIA; ADULT; CANCER RISK; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME POLYMORPHISM; FOLATE METABOLISM; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEMATOPOIETIC STEM CELL; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; XENOBIOTIC METABOLISM; ACUTE DISEASE; CASE CONTROL STUDY; DISEASE PREDISPOSITION; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; LEUKEMIA; METABOLISM; PHYSIOLOGY;

ACUTE DISEASE; ADULT; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE SUSCEPTIBILITY; HUMANS; LEUKEMIA; POLYMORPHISM, GENETIC; VARIATION (GENETICS);

EID: 0036321541     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200202020-00002     Document Type: Review

References (98)

1. Karyotype and age in acute myeloid leukemia. Are they linked?
2. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial
3. Cytochrome P450 CYP2D6
4. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility
5. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias
6. Susceptibility to childhood acute lymphoblastic leukaemia: Influence of CYP1A1, CYP2D6, GSTM1 and GSTT1 genetic polymorphisms
7. Study of the association between cytochromes P450 2D6 and 2E1 genotypes and the risk of drug & chemical-induced idiosyncratic aplastic anaemia
8. Genetic susceptibility to childhood acute lymphoblastic leukemia
9. Metabolisers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia
10. A novel translocation in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metaboliser phenotype for the anticonvulsant drug S-mephenytoin
11. RNA molecules containing exons originating from different members of the cytochrome P4502C gene subfamily (CYP2C) in human epidermis and liver
12. Genetic polymorphisms in human drug metabolic enzymes
13. CYP1A1
14. Metabolism of 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine by human cytochrome P4501A1, P4501A2 and P4501B1
15. PCR detection of an A/G polymorphism within exon 7 of the CYP1A1 gene
16. The role of ethnicity in cancer susceptibility gene polymorphisms: The example of CYP1A1
17. Functional significance of different human CYP1A1 genotypes
18. Drug metabolism polymorphisms as modulators of cancer susceptibility
19. High susceptibility to lung cancer analyzed in terms of combined genotypes of P45OIA1 and Mu-class glutathione S-transferase gene
20. Association of Ile462Val (exon 7) polymorphism of cytochrome P450 1A1 with lung cancer in the Asian population: Further evidence from a case-control study in Okinawa
21. Susceptibility to endometrial cancer: Influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci
22. Cytochrome P4501A1 and glutathione S-transferase M1 genotypes as risk factors for prostate cancer in Japan
23. Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral and squamous cell carcinoma in association with cigarette dose
24. Risk of childhood leukemia associated with exposure to pesticides and with gene polymorphisms
25. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance
26. Strategies to characterize the mechanisms of action and the active sites of glutathione S-transferases: A review
27. Polymorphism in glutathione S-transferase P1 is associated with risk of acute myeloid leukaemia following chemotherapy
28. Polymorphic variation within the glutathione S-transferase genes and risk of adult acute leukaemia
29. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia
30. Glutathione S-transferase theta 1 gene deletion and risk of acute myeloid leukemia
31. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapyrelated leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia
32. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect
33. Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia
34. Glutathione S-transferase theta 1 (GSTT1) gene defect in myelodysplasia and acute myeloid leukaemia
35. Increased prevalence of GSTM(1) null genotype in patients with myelodysplastic syndrome: A case-control study
36. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies
37. Genetic control of acetyl coenzyme A-depend arylamine N-acetyltransferase, hydrazine N-acetyltransferase, and N-hydroxy-arylamine O-acetyltransferase enzymes in C57BL/6J, A/J, AC57F1, and the rapid and slow acetylator A.B6 and B6.A congenic inbred mouse
38. Genotypes of N-acetyltransferase-2 and risk of bladder cancer: A case-control study
39. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking-related bladder cancer
40. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase-2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase and cytochrome P450 enzymes as modulators of bladder cancer risk
41. Human glutathione S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer; oral, lung, gastric, colorectal and urothelial cancer
42. Hepatic acetylator polymorphism in breast cancer patients
43. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk
44. A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer
45. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer
46. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk
47. N-Acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low-risk population
48. Incidence and time trends for lymphomas, leukaemias and myelomas: Hypothesis generation
49. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder
50. NAT2 Acetylator genotypes confer no effect on the risk of developing adult acute leukaemia: A case-control study
51. Genetic polymorphisms of N-acetyltransferases 1 and 2 and gene-gene interaction in the susceptibility to childhood acute lymphoblastic leukemia
52. Metabolic basis of benzene toxicity
53. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609CT mutation and rapid fractional excretion of chlorzoxazone
54. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia
55. Hypothesis: Phenol and hydroquinone derived mainly from diet and gastrointestinal flora activity are causal factors in leukemia
56. An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia
57. Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults
58. The incident of secondary leukaemias
59. Risk of leukaemia after chemotherapy and radiation treatment for breast cancer
60. Comments on the Cox model of cyclophosphamide hematotoxicity
61. Leukemia following chemotherapy for ovarian cancer
62. Leukemia following Hodgkin's disease
63. Second cancers among long-term survivors of non-Hodgkin's lymphoma
64. Risk of leukemia following treatment for non-Hodgkin's lymphoma
65. Second malignant neoplasms among long-term survivors of ovarian cancer
66. Late effects of treatment for childhood Hodgkin's disease
67. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma
68. Risk of second malignant neoplasms among long-term survivors of testicular cancer
69. Risk of leukemia after platinum-based chemotherapy for ovarian cancer
70. Treatment-associated leukemia following testicular cancer
71. DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents
72. Mechanisms of tolerance to DNA damaging therapeutic drugs
73. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements
74. Secondary leukemias induced by topoisomerase-targeted drugs
75. Association of CYP3A4 genotype with treatment-related leukaemia
76. The pathogenesis of homocysteinemia-interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine
77. Presence and consequence of uracil in preneoplastic DNA from folate/methyl-deficient rats
78. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: Implications for cancer and neuronal damage
79. Folate and colorectal cancer: Is DNA repair the missing link?
80. Folate deficiency in rats induces DNA strand breaks and hypomethylation within the p53 tumour suppressor gene
81. Folate, vitamin B12, homocysteine status and chromosome damage rate in lymphocytes of older men
82. Colorectal cancer and folate status: A nested case-control study among male smokers
83. Folate deficiency and cervical intraepithelial neoplasia
84. Folate: Effects on carcinogenesis and the potential for cancer chemoprevention
85. Dietary-folate as a risk factor for neural-tube defects-evidence from a case-control study in Western Australia
86. Moderate folate depletion increases plasma homocystein and decreases lymphocyte DNA methylation in postmenopausal women
87. Homocysteine and ischaemic heart disease in the Caerphilly cohort
88. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukaemia in adults
89. A candidate genetic risk factor for vascular-disease - A common mutation in methylenetetrahydrofolate reductase
90. Mutated methylenetetrahydrofolate reductase as a risk factor for spina-bifida
91. 5,10 Methylenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects
92. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine and risk of myocardial infarction in US physicians
93. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia
94. Spina bifida, 677T→C mutation, and role of folate
95. A common mutation in methylenetetrahydrofolate reductase gene among the Japanese population
96. A second polymorphism in methylene-tetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity